State Street Corp Aveo Pharmaceuticals, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.0 - $15.0 $0 - $1.91 Million	-127,282 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$8.48 - $14.97 $250,948 - $443,007	29,593 Added 30.29%	127,282 $1.9 Million
Q3 2022 Nov 15, 2022	BUY	$6.61 - $8.72 $3,966 - $5,232	600 Added 0.62%	97,689 $804,000
Q1 2022 May 16, 2022	BUY	$3.15 - $6.01 $25,811 - $49,245	8,194 Added 9.22%	97,089 $543,000
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $36,352 - $48,919	-7,100 Reduced 7.4%	88,895 $549,000
Q2 2021 Aug 16, 2021	SELL	$6.21 - $7.45 $1.36 Million - $1.63 Million	-219,192 Reduced 69.54%	95,995 $633,000
Q1 2021 May 17, 2021	BUY	$5.97 - $15.28 $220,412 - $564,137	36,920 Added 13.27%	315,187 $2.31 Million
Q4 2020 Feb 16, 2021	BUY	$5.08 - $6.68 $443,651 - $583,384	87,333 Added 45.74%	278,267 $1.61 Million
Q3 2020 Nov 10, 2020	BUY	$4.16 - $6.26 $247,203 - $371,994	59,424 Added 45.19%	190,934 $1.13 Million
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $456,339 - $1.31 Million	131,510 New	131,510 $677,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.